In terms of clinical characteristics, we found that grade II glioma patients, as well as patients with the IDH mutation, 1p/19q codel, and methylated MGMT promoter were more likely to be in the low immune risk score group (Figure 5A). The gene discussed is IDH1; the disease is central nervous system cancer.